Targeting to Epigenetic Modications in ALL
针对 ALL 的表观遗传修饰
基本信息
- 批准号:8916649
- 负责人:
- 金额:$ 40.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-09-25 至 2016-07-31
- 项目状态:已结题
- 来源:
- 关键词:Acute Lymphocytic LeukemiaAdultAftercareBiochemicalBiologicalBiological AssayCell LineCell ProliferationCell SurvivalCellsCellular AssayChemicalsChildChildhood Acute Lymphocytic LeukemiaClinicalClinical TrialsComplexCytotoxic ChemotherapyDataDevelopmentDiagnosisDiseaseDoctor of MedicineDoctor of PhilosophyDrug KineticsEpigenetic ProcessFundingFutureGene ExpressionGenesGenetic ScreeningHDAC1 geneHDAC2 geneHistone AcetylationHistone Deacetylase InhibitorHumanIn VitroLeadLibrariesMethylationModelingMusOutcomePatientsPloidiesPreclinical TestingPrincipal InvestigatorPropertyRNA InterferenceRelapseRoleStructureTherapeuticTherapeutic InterventionTranslatingTranslationsWorkXenograft ModelXenograft procedureassay developmentbasechemotherapeutic agentchemotherapyclinical investigationcytotoxicdesigngenome-widehigh throughput screeninghistone methylationhistone methyltransferasehistone modificationhuman diseasein vivoinhibitor/antagonistleukemiamembermouse modelnovelnovel strategiespre-clinicalprogramsprototyperesearch clinical testingresponsescreeningsmall hairpin RNAsmall moleculetherapeutic target
项目摘要
Increased understanding ofthe epigenetic mechanisms that control gene expression programs important for
leukemia development and survival provides exciting new opportunities for therapeutic intervention.
Specifically, methylation or acetylation of histones maintains gene expression programs necessary for
leukemia cell proliferation and survival. The central hypothesis for this project is that small molecule
inhibitors of histone modifications will effectively target acute lymphoblastic leukemia (ALL) cells.
We will assess this through the use novel small molecules, chemical biological approaches, novel mouse
models and genetic screens. In specific aim 1 we will work to define a role for D0T1L inhibition in MLL-
Rearranged ALL through characterization of a potent, specific D0T1L inhibitor that has remarkably selective
anti-proliferative and proapoptotic effects on MLL-rearranged ALL cells. In aim 2 we will develop assays and
use novel chemical approaches for high-throughput identification of new small molecule DOT1L inhibitors. In
specific aim 3 we will work with to develop rationale for clinical development of histone deacetylase (HDAC)
inhibitors as therapies for ALL, with a particular focus on leukemias that result in high end-induction MRD.
We will also determine rational combinations of HDAC inhibitors and proapototic molecules and with ploidy-
specific agents, and evaluate specific HDAC1 and HDAC2 inhibitors as potential ALL-directed therapeutics.
Based on preclinical data, we will assess HDAC inhibitors in relapsed ALL. We expect these aims to bring
new more efficacious, less toxic therapies to children and adults diagnosed with ALL.
RELEVANCE (See instmctions):
While improvements have been made in the treatment of childhood acute lymphoblastic leukemia (ALL),
children diagnosed with ALL harboring MLL-rearrangements continue to do poody. Also, specific subsets of
children and most adults diagnosed with ALL continue to have poor outcomes. In this project we will
characterize new small molecules that target D0T1L, a histone methyltransferase important for survival of
yWLL-rearranged leukemias. We will also assess both pan-histone deacetylase (HDAC) inhibitors and newly
developed HDAC1/HDAC2 specific inhibitors as potential therapeutics against ALL cells.
增加对控制基因表达程序的表观遗传机制的理解,这对于
白血病的发展和生存为治疗干预提供了令人兴奋的新机会。
具体来说,组蛋白的甲基化或乙酰化维持了基因表达所需的程序
白血病细胞增殖和存活。该项目的中心假设是小分子
组蛋白修饰抑制剂将有效靶向急性淋巴细胞白血病(ALL)细胞。
我们将通过使用新型小分子、化学生物学方法、新型小鼠来评估这一点
模型和遗传筛选。在具体目标 1 中,我们将努力确定 D0T1L 抑制在 MLL-中的作用
通过对具有显着选择性的有效、特异性 D0T1L 抑制剂进行表征,重排了 ALL
对 MLL 重排 ALL 细胞具有抗增殖和促凋亡作用。在目标 2 中,我们将开发检测方法并
使用新颖的化学方法高通量鉴定新型小分子 DOT1L 抑制剂。在
具体目标 3 我们将合作制定组蛋白脱乙酰酶 (HDAC) 临床开发的基本原理
抑制剂作为 ALL 的治疗方法,特别关注导致高端诱导 MRD 的白血病。
我们还将确定 HDAC 抑制剂和促凋亡分子以及倍性的合理组合
特定药物,并评估特定 HDAC1 和 HDAC2 抑制剂作为潜在的 ALL 导向疗法。
根据临床前数据,我们将评估 HDAC 抑制剂在复发性 ALL 中的作用。我们期望这些目标能够带来
为诊断患有 ALL 的儿童和成人提供更有效、毒性更小的新疗法。
相关性(参见说明):
虽然儿童急性淋巴细胞白血病 (ALL) 的治疗已取得进展,
被诊断患有携带 MLL 重排的 ALL 的儿童继续表现不佳。此外,特定子集
被诊断患有 ALL 的儿童和大多数成人的预后仍然不佳。在这个项目中我们将
表征靶向 D0T1L 的新小分子,D0T1L 是一种对生存至关重要的组蛋白甲基转移酶
yWLL 重排白血病。我们还将评估泛组蛋白脱乙酰酶 (HDAC) 抑制剂和新的
开发了 HDAC1/HDAC2 特异性抑制剂作为针对 ALL 细胞的潜在疗法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SCOTT A ARMSTRONG其他文献
SCOTT A ARMSTRONG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SCOTT A ARMSTRONG', 18)}}的其他基金
The Center for Therapeutic Targeting of EWS-oncoproteins
EWS癌蛋白治疗靶向中心
- 批准号:
10671815 - 财政年份:2022
- 资助金额:
$ 40.23万 - 项目类别:
The Center for Therapeutic Targeting of EWS-oncoproteins
EWS癌蛋白治疗靶向中心
- 批准号:
10382013 - 财政年份:2021
- 资助金额:
$ 40.23万 - 项目类别:
Defining epigenetic mechanisms in NPM1c mutant leukemia
定义 NPM1c 突变白血病的表观遗传机制
- 批准号:
10184546 - 财政年份:2021
- 资助金额:
$ 40.23万 - 项目类别:
Defining epigenetic mechanisms in NPM1c mutant leukemia
定义 NPM1c 突变白血病的表观遗传机制
- 批准号:
10640846 - 财政年份:2021
- 资助金额:
$ 40.23万 - 项目类别:
Defining epigenetic mechanisms in NPM1c mutant leukemia
定义 NPM1c 突变白血病的表观遗传机制
- 批准号:
10388249 - 财政年份:2021
- 资助金额:
$ 40.23万 - 项目类别:
Targeting DOT1L for Degradation in MLL-rearranged Leukemia
靶向 DOT1L 降解 MLL 重排白血病
- 批准号:
10411945 - 财政年份:2012
- 资助金额:
$ 40.23万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 40.23万 - 项目类别:
Research Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 40.23万 - 项目类别:
Standard Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 40.23万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 40.23万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 40.23万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 40.23万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 40.23万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 40.23万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 40.23万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 40.23万 - 项目类别:
Grant-in-Aid for Scientific Research (C)